Hangzhou Alltest Biotech Co. Ltd. A (688606) — Cash Flow-to-Debt Ratio
Hangzhou Alltest Biotech Co. Ltd. A (688606) has a Cash Flow-to-Debt Ratio of 0.16x as of September 2025, meaning its operating cash flow of CN¥55.21 Million could theoretically repay 0% of its total liabilities (CN¥340.68 Million) in one year. See Hangzhou Alltest Biotech Co. Ltd. A free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou Alltest Biotech Co. Ltd. A Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Hangzhou Alltest Biotech Co. Ltd. A across 10 annual periods. Also explore Hangzhou Alltest Biotech Co. Ltd. A equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
Year-by-year debt coverage analysis for Hangzhou Alltest Biotech Co. Ltd. A. For market capitalisation and broader financial context, see 688606 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.70x | CN¥206.59 Million | CN¥296.09 Million | ▼ -35.9% |
| 2024 | 1.09x | CN¥329.52 Million | CN¥302.60 Million | ▲ +1151.1% |
| 2023 | 0.09x | CN¥24.76 Million | CN¥284.50 Million | ▼ -96.6% |
| 2022 | 2.57x | CN¥1.36 Billion | CN¥528.80 Million | ▲ +104.6% |
| 2021 | 1.26x | CN¥923.87 Million | CN¥734.71 Million | ▼ -64.0% |
| 2020 | 3.49x | CN¥622.72 Million | CN¥178.45 Million | ▲ +49.8% |
| 2019 | 2.33x | CN¥91.53 Million | CN¥39.30 Million | ▲ +394.2% |
| 2018 | 0.47x | CN¥18.60 Million | CN¥39.47 Million | ▲ +22.5% |
| 2017 | 0.38x | CN¥19.99 Million | CN¥51.97 Million | ▲ +85.7% |
| 2016 | 0.21x | CN¥6.72 Million | CN¥32.42 Million | — |